Science Explorer Back to mapMap

Most cited papers from Protalix BioTherapeutics (Israel)

What are the most cited papers from Protalix BioTherapeutics (Israel)?

The most cited paper from Protalix BioTherapeutics (Israel) is "Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system" (Yoseph Shaaltiel, Daniel Bartfeld, Sharon Hashmueli et al., 2007), with 433 citations. Next come "The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): A novel, pleiotropic member of the C-X-C chemokine superfamily" (357) and "Small interfering RNA Inhibits Hepatitis B virus replication in mice" (308).

Showing 50 of 59 papers. Every paper with more than 7 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system Yoseph Shaaltiel, Daniel Bartfeld, Sharon Hashmueli et al. · Plant Biotechnology Journal Open access 24 May 2007 433
2 The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): A novel, pleiotropic member of the C-X-C chemokine superfamily Lewis F. Neville, Guenther Mathiak, Omar Bagasra · Cytokine & Growth Factor Reviews Review Sep 1997 357
3 Small interfering RNA Inhibits Hepatitis B virus replication in mice Hilla Giladi, Mali Ketzinel‐Gilad, Ludmila Rivkin et al. · Molecular Therapy Open access Nov 2003 308
4 Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease Ari Zimran et al. · Blood Open access 7 Sep 2011 210
5 Large‐scale production of pharmaceutical proteins in plant cell culture—the protalix experience Yoram Tekoah, Avidor Shulman, Tali A. Kizhner et al. · Plant Biotechnology Journal Open access 23 Jun 2015 193
6 Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technology Gregory Alex Grabowski, Myriam Golembo, Yoseph Shaaltiel · Molecular Genetics and Metabolism 2 Mar 2014 155
7 Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial Raphael Schiffmann et al. · Journal of Inherited Metabolic Disease Open access 5 Mar 2019 141
8 Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease Tali A. Kizhner, Yaniv Azulay, Mariana Hainrichson et al. · Molecular Genetics and Metabolism Open access 10 Aug 2014 130
9 Crystal Structures of Complexes of N-Butyl- and N-Nonyl-Deoxynojirimycin Bound to Acid β-Glucosidase Boris Brumshtein, Harry M. Greenblatt, Terry D. Butters et al. · Journal of Biological Chemistry Open access 31 Jul 2007 122
10 Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study Thomas D. Schiano, Michael Charlton, Zobair M. Younossi et al. · Liver Transplantation 2006 117
11 Establishment of a tobacco BY2 cell line devoid of plant‐specific xylose and fucose as a platform for the production of biotherapeutic proteins Uri Hanania, Tami Ariel, Yoram Tekoah et al. · Plant Biotechnology Journal Open access 3 Feb 2017 111
12 Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant Patients Rachel Eren et al. · Journal of Virology Open access 24 Feb 2006 102
13 Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems Yoram Tekoah, Salit Tzaban, Tali A. Kizhner et al. · Bioscience Reports Open access 29 Aug 2013 100
14 The Hepatitis B Virus-Trimera Mouse: A Model for Human Hbv Infection and Evaluation of Anti–Hbv Therapeutic Agents Ehud Ilan, Tatjana Burakova, Shlomo Dagan et al. · Hepatology Open access Feb 1999 98
15 The Hepatitis C Virus (HCV)–Trimera Mouse: A Model for Evaluation of Agents against HCV Ehud Ilan, Joseph Arazi, Ofer Nussbaum et al. · The Journal of Infectious Diseases 15 Jan 2002 93
16 Preclinical Evaluation of Two Human Anti-Hepatitis B Virus (HBV) Monoclonal Antibodies in the HBV-Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees Rachel Eren, Ehud Ilan, Ofer Nussbaum et al. · Hepatology Open access Sep 2000 84
17 Novel Mechanism of Antibodies to Hepatitis B Virus in Blocking Viral Particle Release from Cells† Avidan Uriel Neumann, S M Phillips, Idit Levine et al. · Hepatology Open access 27 May 2010 81
18 Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial Zachary David Crees et al. · Nature Medicine Open access Apr 2023 79
19 Plant specific N-glycans do not have proven adverse effects in humans Yoseph Shaaltiel, Yoram Tekoah · Nature Biotechnology Jul 2016 71
20 Plant‐based oral delivery of β‐glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease Yoseph Shaaltiel, Svetlana Gingis‐Velitski, Salit Tzaban et al. · Plant Biotechnology Journal Open access Apr 2015 71
21 Caspase‐1‐inhibitor ac‐YVAD‐cmk reduces LPS‐lethality in rats without affecting haematology or cytokine responses Guenther Mathiak, Guido Grass, Thomas Herzmann et al. · British Journal of Pharmacology Open access Oct 2000 66
22 A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase Gregory M. Pastores, Milan S. Petakov, Pilar Giraldo et al. · Blood Cells Molecules and Diseases 18 Jun 2014 60
23 Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story Bonita J. Rup, Sari Alon, Bat-Chen Amit-Cohen et al. · PLoS ONE Open access 31 Oct 2017 55
24 Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study Eric L Wallace et al. · Journal of Medical Genetics Open access 8 Nov 2023 49
25 6‐Amino‐6‐deoxy‐5,6‐di‐ N ‐( N ′‐octyliminomethylidene)nojirimycin: Synthesis, Biological Evaluation, and Crystal Structure in Complex with Acid β‐Glucosidase Boris Brumshtein, Matilde Aguilar‐Moncayo, M. Isabel García‐Moreno et al. · ChemBioChem 13 May 2009 48
26 The Trimera mouse: generating human monoclonal antibodies and an animal model for human diseases Yaīr Reisner, Shlomo Dagan · Trends in biotechnology Review Jun 1998 44
27 Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, Aya Abrahamov et al. · Blood Cells Molecules and Diseases Open access 20 Oct 2016 43
28 HUWE1 ubiquitinates MyoD and targets it for proteasomal degradation Tahel Noy, Oded Suad, Daniel Taglicht et al. · Biochemical and Biophysical Research Communications 19 Jan 2012 41
29 Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: Safety and antiviral activity Eithan Galun, Norah A. Terrault, Rachel Eren et al. · Journal of Hepatology Open access 21 Oct 2006 41
30 Development and Analytical Characterization of Pegunigalsidase Alfa, a Chemically Cross-Linked Plant Recombinant Human α-Galactosidase-A for Treatment of Fabry Disease Ilya Ruderfer, Avidor Shulman, Tali A. Kizhner et al. · Bioconjugate Chemistry 26 Apr 2018 40
31 Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease Laura van Dussen, Ari Zimran, Erik M. Akkerman et al. · Blood Cells Molecules and Diseases 28 Nov 2012 38
32 Cell-Based and Animal Models for Hepatitis B and C Viruses Raymond F. Schinazi, Ehud Ilan, Paul L. Black et al. · Antiviral chemistry & chemotherapy Open access Jun 1999 36
33 Therapy with anti-flagellin A monoclonal antibody limits Pseudomonas aeruginosa invasiveness in a mouse burn wound sepsis model Yoav Barnea, Yehuda Carmeli, Lewis F. Neville et al. · Burns Nov 2008 35
34 Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, Aya Abrahamov et al. · Blood Cells Molecules and Diseases Open access 7 Nov 2014 35
35 Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study Aleš Linhart, Gabriela Dostálová, Kathy Nicholls et al. · Orphanet Journal of Rare Diseases Open access 21 Oct 2023 34
36 Antibodies raised against N'-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection Lewis F. Neville, Yoav Barnea, Orly Hammer-Münz et al. · International Journal of Molecular Medicine Jul 2005 33
37 Cyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues Boris Brumshtein, Matilde Aguilar‐Moncayo, Juan Manuel Benito et al. · Organic & Biomolecular Chemistry Open access 2011 32
38 Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase Gregory M. Pastores, Suma P. Shankar, Milan S. Petakov et al. · American Journal of Hematology Open access 22 Apr 2016 29
39 Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease Derralynn A. Hughes, Derlis Gonzalez, Gustavo H. B. Maegawa et al. · Genetics in Medicine Open access 24 Aug 2023 28
40 Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naïve patients with Gaucher disease Ari Zimran, Gloria Durán, Pilar Giraldo et al. · Blood Cells Molecules and Diseases Open access 18 Jul 2016 28
41 GENESIS: Phase III Trial Evaluating BL-8040 + G-CSF to Mobilize Hematopoietic Cells for Autologous Transplant in Myeloma Zachary David Crees, Keith E Stockerl-Goldstein, Abi Vainstein et al. · Future Oncology Open access 9 Sep 2019 25
42 Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease Ari Zimran, Gloria Durán, Atul B Mehta et al. · American Journal of Hematology Open access 19 Mar 2016 24
43 Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model Luc Bracoud, Harris Ahmad, Einat Brill‐Almon et al. · Blood Cells Molecules and Diseases 18 Nov 2010 23
44 Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis Yaron Ilan, Ami Ben Yaʼacov, Yehudit Shabbat et al. · World Journal of Gastroenterology Open access 2016 22
45 Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R Jacob Atsmon, Einat Brill‐Almon, Carmit Nadri-Shay et al. · Toxicology and Applied Pharmacology 6 Jun 2015 20
46 CHEMOKINES AND INTERLEUKIN-18 ARE UP-REGULATED IN BRONCHOALVEOLAR LAVAGE FLUID BUT NOT IN SERUM OF SEPTIC SURGICAL ICU PATIENTS Guenther Mathiak, Lewis F. Neville, Guido Grass et al. · Shock Mar 2001 19
47 The use of the hydrodynamic HBV animal model to study HBV biology and anti-viral therapy Mali Ketzinel‐Gilad, Arie Zauberman, Ofer Nussbaum et al. · Hepatology Research 8 Mar 2006 18
48 Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor Zachary David Crees, Michael P. Rettig, Asad Bashey et al. · Blood Advances Open access 16 Jun 2023 17
49 A phase III , open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies Myrl D. Holida, Aleš Linhart, Antonio Pisani et al. · Journal of Inherited Metabolic Disease Open access 9 Oct 2024 16
50 Nonlinear focusing of DNA macromolecules Leonid L. Frumin, Sergey Evgenyevich Peltek, Gleb V. Zilberstein · Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics 17 Jul 2001 15

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.